Revisiting Determinants of Prognosis in Cutaneous Melanoma
|
|
- Allen Paul
- 6 years ago
- Views:
Transcription
1 Review Article Revisiting Determinants of Prognosis in Cutaneous Melanoma Sarah A. Weiss MD 1,2 ; Douglas Hanniford PhD 2,3 ; Eva Hernando PhD 2,3 ; and Iman Osman MD 1,2,4 The American Joint Committee on Cancer staging system for cutaneous melanoma is based on primary tumor thickness and the presence of ulceration, mitoses, lymph node spread, and distant metastases as determinants of prognosis. Although this cutaneous melanoma staging system has evolved over time to more accurately reflect patient prognosis, improvements are still needed, because current understanding of the particular factors (genetic mutation, expression alteration, host response, etc) that are critical for predicting patient outcomes is incomplete. Given the clinical and biologic heterogeneity of primary melanomas, new prognostic tools are needed to more precisely identify patients who are most likely to develop advanced disease. Such tools would affect clinical surveillance strategies and aid in patient selection for adjuvant therapy. The authors reviewed the literature on prognostic molecular and immunologic markers in primary cutaneous melanoma, their associations with clinicopathologic and survival outcomes, and their potential for incorporation into current staging models. Overall, the studies considered in this review did not define prognostic markers that could be readily incorporated into the current staging system. Therefore, efforts should be continued in these and other directions to maximize the likelihood of identifying clinically useful prognostic biomarkers for cutaneous melanoma. Cancer 2015;121: VC 2015 American Cancer Society. KEYWORDS: biomarkers, genetics, melanoma, messenger RNA, micrornas, prognostic, staging, tumor-infiltrating lymphocytes. INTRODUCTION Melanoma is increasing in incidence. In 2014, there were over 76,000 new melanoma cases and greater than 9000 melanoma-related deaths in the United States. 1 The current American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma is based on primary tumor thickness and the presence of ulceration, mitoses, lymph node spread, and distant metastases as determinants of prognosis. However, survival outcomes can vary widely even within the same stage. Given the clinical and biologic heterogeneity of primary melanoma, new prognostic tools are needed to more precisely identify which patients are most likely to develop advanced disease. Such tools would affect clinical surveillance strategies and aid in patient selection for adjuvant therapy. Here, we discuss the evolution of primary melanoma prognostic determinants, their limitations, and the current literature on melanoma prognostic markers from a molecular and immunologic perspective. The Evolution of Cutaneous Melanoma Staging Over Time In the mid-20th century, melanoma staging and, thus, prognosis were driven by thickness and level of invasion. In 1969, Clark et al 2 described 5 levels of primary melanoma tumor invasion that inversely correlated with overall survival (OS) in a study of 208 primary melanomas. 2 Breslow 3 also observed that tumor thickness combined with Clark level produced the most accurate prognoses in a cohort of 98 patients who had primary melanomas examined for Clark level, tumor thickness, and cross-sectional area (thickness times greatest tumor dimension). No melanoma recurrences or metastases from primary tumors <0.76 mm thick in Clark level II and III tumors occurred within 5 years of follow-up; thus, 0.76 mm was recommended as a cutoff point to stratify patients for lymph node dissection. 3 Corresponding authors: Iman Osman, MD, New York University Langone Medical Center, 522 First Avenue, Smilow 405, New York, NY 10016; Fax: (212) ; iman.osman@nyumc.org; Eva Hernando-Monge, PhD, New York University Langone Medical Center, 522 First Avenue, Smilow 305, New York, NY 10016; Fax: (212) ; eva.hernando-monge@nyumc.org 1 Department of Medical Oncology, New York University School of Medicine, New York, New York; 2 Interdisciplinary Melanoma Cooperative Group, New York University School of Medicine, New York, New York; 3 Department of Pathology, New York University School of Medicine, New York, New York; 4 Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York. Additional supporting information may be found in the online version of this article. DOI: /cncr.29634, Received: May 19, 2015; Revised: July 9, 2015; Accepted: July 13, 2015, Published online August 26, 2015 in Wiley Online Library (wileyonlinelibrary.com) 4108 Cancer December 1, 2015
2 Determinants of Prognosis in Melanoma/Weiss et al Since those seminal studies, melanoma staging has continued to evolve as patient cohorts have expanded and additional prognostic features have been described. Today, the AJCC oversees melanoma staging guidelines, which incorporate tumor thickness and other histopathologic parameters into the TNM (tumor, lymph node, metastasis) criteria used for most solid tumors. In 2002, the AJCC made significant changes to the melanoma staging system, including increasing thickness thresholds for tumor classification from 0.75, 1.5, and 4 mm to 1, 2, and 4 mm and including ulceration status as a second determinant of tumor classification based on a multivariate analysis of 13,581 patients with primary melanoma. 4,5 In addition, in a subset of 4750 patients without clinically detected lymph node metastases, the Clark level was predictive of outcome in those who had thin melanomas (<1 mm), whereas ulceration was the most prognostic factor in those who had thicker melanomas (1 mm). 5 Other AJCC staging updates at that time included shifting thick T4 melanomas from stage IIIA to stage IIC, the inclusion of satellite metastases in lymph node staging, and exclusion of the size of lymph node metastases, which was no longer considered prognostic. 5-7 In 2010, the mitotic rate (1/mm 2 ) replaced the Clark level for characterizing T1 melanomas when a multivariate analysis of 4861 T1 primary melanomas demonstrated that thickness, mitotic rate, and ulceration significantly predicted survival outcomes, whereas Clark level did not. 7 The inclusion of mitoses in melanoma staging was considered practice-changing. Because of a 10% risk of sentinel lymph node (SLN) positivity for a primary tumor thickness from 0.76 to 1.0 mm with mitoses, surgeons may now be prompted to offer SLN biopsy to patients who have thinner melanomas if mitoses are present. 8 In addition, a lymph node was defined as positive if any isolated tumor cells were detected histologically or by immunohistochemistry (IHC), whereas at least 0.2 mm of tumor was previously required for positivity. This also changed prognostic discussions that clinicians have with these patients, who are now being upstaged to at least stage IIIA melanoma for even a single tumor cell noted in the lymph node, conferring a worse prognosis. 7,8 Limitations of the AJCC Staging System Although the AJCC cutaneous melanoma staging system has evolved over time to more accurately reflect patient prognosis, improvements are still needed. TNM staging does not always reliably predict patient outcomes by stage. For example, stage I melanomas 1 mm comprise the majority (approximately 80%) of melanoma diagnoses reported to the National Cancer Institute s Surveillance, Epidemiology, and End Results Cancer Registry and carry an excellent prognosis, with 5-year OS rates from 92% to 97%. 9,10 However, 15% of these patients die from melanoma. 10 Furthermore, patients who have stage IIC melanomas have a worse 5-year OS (53%) compared with those who have stage IIIA melanomas (78%); and patients who have stage III melanomas have a highly variable 5-year OS rate, which ranges from 78%, 59%, and 50% for stage IIIA, IIIB, and IIIC melanomas, respectively. 9,11 It has been hypothesized that adding measurements of host antitumor immune response and/or molecular features to staging may improve primary melanoma prognostication. New tumor-based, host-based, and/or blood-based biomarkers to address the inconsistencies of an ever-evolving, imperfect staging system are critically needed. For this report, we reviewed the literature on prognostic molecular and immunologic markers in primary cutaneous melanoma, their associations with clinicopathologic and survival outcomes, and their potential for incorporation into current staging models. TISSUE-BASED MOLECULAR GENETIC MARKERS Identifying tissue-based prognostic molecular markers in melanoma has been challenging. One major limitation is that most primary melanomas are preserved as formalinfixed, paraffin-embedded (FFPE) samples rather than fresh-frozen tissues because of the small size of the specimens. High-quality genetic material is less commonly extractable from FFPE samples, precluding their use with early generation sequencing methods. 12 The relative stability of messenger RNA (mrna) is also inconsistent in FFPE samples. 13 However, improved extraction methods; newer technologies; and novel, stable RNA molecules, such as microrna (mirna), have allowed exome-wide or genome-wide mutational analysis or RNA expression profiling from small amounts of genetic material isolated from FFPE samples. 12 Such technical and biologic advances have yielded new insights into melanoma biology and new molecules for prognostic assessment. Genes that were initially identified as genetically altered drivers of melanoma tumorigenesis (v-raf murine sarcoma viral oncogene homolog B [BRAF], neuroblastoma RAS viral oncogene homolog [NRAS], phosphatase and tensin homolog [PTEN], etc) were captured in candidate-based analyses focused on known proliferation and survival pathways. Next-generation sequencing (NGS) has afforded an unprecedented depth of knowledge of the mutational landscape of entire melanoma Cancer December 1,
3 Review Article genomes, which has confirmed and expanded on these findings However, challenges remain in identifying the genetic drivers of melanomagenesis and progression. A comprehensive analysis of whole-exome sequencing data from 21 tumor types (The Cancer Genome Atlas and the Broad Institute) calculated that sequencing information for >5000 samples is required to identify all enriched, mutated genes present in >2% of melanomas at 90% power, 18 highlighting the particular challenge of interpreting sequencing data for melanoma. Moreover, among the genes nominated from melanoma NGS studies, few reports have associated individual mutations with clinical outcomes or have studied their use as prognostic biomarkers in cutaneous melanoma. Nonetheless, there has been a movement to genetically define melanomas; and, in this report, we review the associations between patient prognosis and commonly mutated genes in melanoma. BRAF Activating BRAF mutations are present in 50% to 60% of melanomas, the majority of which are codon 600 valineto-glutamic acid (V600E) (approximately 90%) or valineto-lysine (V600K) (approximately 10%) mutations. 19 BRAF mutations have been described with high frequency in benign nevi, although they occur less frequently in radial growth phase than in vertical growth phase melanomas, suggesting that oncogenic BRAF mutations are associated with melanoma progression more strongly than with melanomagenesis. 20 There are conflicting data on BRAF mutation status as an independent prognostic marker in melanoma. A meta-analysis has indicated that patients who have BRAF-mutant tumors have a 1.7-fold increased risk of death compared with those who have BRAF wild-type (WT) tumors. 22 In contrast, many small studies of primary melanomas cite no independent association between BRAF mutation status and survival (Table 1), 22,23,25,28 although Ellerhorst et al did observe that BRAF-mutant primary melanomas may have more adverse pathologic characteristics (increased thickness and ulceration) compared with WT tumors and tend to present clinically with higher stage disease. 23 NRAS NRAS mutations, which occur in about 15% of cutaneous melanomas, most commonly at codon 61 (glutamine to lysine [Q61K] or to arginine [Q61R]), also lead to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. 22,23 Similar to BRAF mutations, the prognostic implications of NRAS mutations vary in the literature (Table 1). Devitt et al prospectively studied 249 primary melanomas and observed that patients with NRAS-mutant melanoma (codon 61) had shorter melanoma-specific survival (MSS) (hazard ratio [HR], 2.51; P 5.05) and trended toward worse recurrence-free survival (RFS) in multivariate analysis (HR, 2.08; P 5.09), but NRAS mutation status had no impact on OS (HR, 1.47; P 5.37). 24 NRAS-mutated primary melanomas tended to be thicker, had more mitoses, and more frequently were of the nodular subtype compared with BRAF-mutant or NRAS/BRAF-WT tumors. 24 Multiple other studies of primary melanomas have indicated no association of NRAS mutation status with RFS, MSS, or OS. 23,25 Most recently, investigators from the Genes, Environment, and Melanoma study reported on associations of BRAF and NRAS status with clinicopathologic variables and MSS in 912 patients with primary melanoma. The 7.6-year median follow-up was completed before 2011, which limits the possible confounders of targeted or immunotherapy administration in patients who progressed. Although there were no differences in 5-year OS between patients who had BRAF-mutant, NRAS-mutant, or WT tumors, there was a 3-fold increase in melanomarelated death in patients who had BRAF-mutant and NRAS-mutant tumors, specifically in the high-risk category (T2b or above), compared with those who had WT tumors. 27 V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene The v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene (KIT) is a type III receptor tyrosine kinase for stem cell factor and functions as an oncogene involved in melanocytic differentiation, migration, proliferation, and survival. 29,30 KIT mutations or gene amplifications occur in 10% to 25% of melanomas arising from areas of acral, mucosal, or sun-damaged skin; they are rare (range, 0%- 2%) in cutaneous melanomas without chronic sundamage; and they can rarely coexist with BRAF mutations. 29,31,32 There is limited information on the prognostic significance of KIT in melanoma, although melanoma subtypes associated with KIT mutation have a worse overall prognosis compared with more common cutaneous melanomas. 33 PTEN The tumor suppressor PTEN functions as a phosphatase that, when inactivated, results in constitutive activation of 4110 Cancer December 1, 2015
4 Determinants of Prognosis in Melanoma/Weiss et al TABLE 1. Prognostic Implications of Genetic Mutations in Melanoma Study Population Clinicopathologic Associations Survival Associations Reference BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutation Primary melanomas (n 5 89) Truncal location, superficial spreading No association with development of Maldonado histologic subtype, younger age metastases or MSS Primary melanomas (n 5 223) Higher rate of ulceration No association with survival Ellerhorst outcomes Primary melanomas (n 5 249) Worse RFS in multivariate analysis Devitt adjusting for age, sex, tumor site, tumor stage, mitosis, and ulceration, but not in a second multivariate analysis, which also controlled for thickness Meta-analysis of 4 melanoma studies A 1.7-fold increased risk of death Safaee Ardekani Primary nodular melanomas (n 5 51) Higher rate of ulceration in primary No association with RFS or MSS Akslen and paired metastases (n 5 18) tumor Melanoma lymph node metastases Worse survival outcome Mann and their associated primaries (n 5 79) Primary melanomas (n 5 912) Younger age, superficial spreading histologic subtype, present mitoses A 3-fold-increased risk of melanoma-related death compared with WT for high-risk patients after adjustment for age, sex, study center, anatomic site, and TIL grade Thomas NRAS (neuroblastoma RAS viral oncogene homolog) mutation Primary melanomas (n 5 223) Thicker, upper extremity location No association with OS Ellerhorst Primary melanomas (n 5 249) Thicker, higher mitotic rates; trend Association with shorter MSS Devitt toward higher proliferation as measured by Ki-67 Primary melanomas (n 5 51) and No association with RFS or MSS Akslen paired metastases (n 5 18) Melanoma lymph node metastases and Worse survival outcome Mann their associated primaries (n 5 79) Primary melanomas (n 5 912) Lower TIL grade, presence of mitoses, anatomic site other than scalp/neck A 3-fold-increased risk of melanoma-related death compared with WT for high-risk patients after adjustment for age, sex, study center, anatomic site, and TIL grade Thomas Abbreviations: MSS, melanoma-specific survival; OS, overall survival; RFS, recurrence-free survival; TIL, tumor-infiltrating lymphocytes; WT, wild type. phosphoinositide 3-kinase/protein kinase B signaling and increased cell survival. 34 Up to 10% of cutaneous melanomas harbor loss-of-function alterations in PTEN, including mutations, deletions, and promoter methylation. 35 In a study of 127 primary melanomas, decreased PTEN protein abundance was associated with primary tumor ulceration, but not with survival outcomes. 34 In contrast, a recent study reported that patients who had tumors with PTEN methylation had worse OS compared with those who had PTEN-unmethylated tumors. 36 PTEN is inactivated by multiple mechanisms, and future outcome association studies ideally should incorporate all mechanisms that contribute to and define PTEN-inactivated tumors. Newly Identified Genetic Mutations NGS studies have expanded the known mutational landscape of melanoma and have nominated novel mutations as drivers of melanoma tumorigenesis. A literature review reveals that only a few studies to date have examined prognostic associations of these newly identified genetic mutations. A mix of recurrent and nonrecurrent mutations in protein phosphatase 6 (PPP6C) recently was identified in 9% to 12% of melanomas. 15,17 Consistent with previous reports, our group recently reported PPP6C mutations in 25 of 233 (10.7%) and 8 of 77 (10.4%) primary and metastatic melanoma samples, respectively. 37 In that report, we documented that, among patients with AJCC stage I through III melanoma, those who had stop mutations trended toward worse RFS, whereas those who had nonstop mutations trended toward improved RFS compared with patients who had WT PPP6C tumors. Although they are identified in only 5% to 9% of melanomas, mutations in Ras-related C3 botulinum toxin substrate 1 (RAC1) are predominantly codon 29 prolineto-serine (P29S) missense mutations that yield aberrant Cancer December 1,
5 Review Article RAC activity, which drives melanoma proliferation and tumorigenesis. 15,17 A recent study indicated that only 27 of 814 (3.3%) primary cutaneous melanomas harbored RAC1 P29S mutations, 38 suggesting that these mutations occur as later events in the natural history of melanoma and may be key drivers of metastatic spread. Consistent with this notion, RAC1 mutations were associated with lymph node spread at diagnosis in addition to other negative prognostic indicators. Unfortunately, that study did not report associations of RAC1 P29S mutation status with distant metastasis or patient outcomes, precluding a definitive assessment. Recurrent mutations in regulatory regions of several genes that aberrantly activate expression of these genes have also recently been described Of these, recurrent mutations in the promoter of telomerase reverse transcriptase (TERT) that create novel ETS family transcription factor binding sites have been documented in up to 70% of melanoma patient samples. TERT promoter mutations result in increased telomerase expression, thus favoring chromosomal stability through maintenance of telomere length, which may improve the fitness of cancer cells harboring such mutations. Two recent studies indicated that TERT promoter mutations (43% and 22% of patients) in primary melanomas were associated with key prognostic parameters (tumor thickness, ulceration, and mitotic rates) and poor disease-free survival (DFS) and OS. 42,43 Collectively, these findings support the potential relevance of newly identified genetic mutations as clinically useful prognostic factors, and further studies to analyze associations of genetic mutations with patient outcomes are warranted. Increased collaboration among research centers to stimulate sample and data pooling and to standardize statistical methods and analyses will aid in a more definitive assessment of genetic mutations as prognostic markers. EXPRESSION OF PROTEIN-CODING GENES Expression level-based analyses of mrnas and proteins provide immensely alluring molecular markers, because these potential markers measure in the tens of thousands. In theory, proteins have a distinct advantage of being the functional end products of protein-coding genes. Moreover, their stability, modifications, and localization multiply their potential as prognostic markers. However, tools to measure proteins genome-wide are still developing; and, to date, the protein-based (IHC) biomarker studies reported in melanoma have largely taken candidate approaches. Several comprehensive reviews and/or metaanalyses have examined protein-based biomarker studies in melanoma ; thus, we refer readers to those excellent articles instead of addressing them in depth here. Briefly, we do note 3 important multimarker prognostic signature studies that have been developed with the use of tissue microarray-based IHC. 44,48 Gould Rothberg et al built a 5-protein signature (high nonnuclear/nuclear activating transcription factor 2 [ATF2], high nuclear cyclin-dependent kinase inhibitor 1 [p21], high total b-catenin, low nonnuclear/nuclear cyclin-dependent kinase inhibitor 2A [p16], and low total fibronectin; from 20 candidates evaluated) that was indicative of a favorable prognosis (OS) using immunofluorescence-based, automated quantitative analysis histochemistry in 192 AJCC stage II FFPE specimens. 44 Those authors validated their scoring method in a set of 226 additional patients with primary melanoma. In contrast, Meyer et al developed a 7-marker signature (B-cell lymphoma 2 [Bcl-2] associated X protein [Bax], Bcl-2 related apoptosis regulator [Bcl-X], PTEN, cyclooxygenase 2 [COX-2], b-catenin loss, methylthioadenosine phosphorylase [MTAP] loss, and the presence of cluster of differentiation 20 [B-lymphocyte antigen; CD20]-positive B lymphocytes, from 70 candidates evaluated) that was indicative of a poor prognosis (RFS and OS) in training (n 5 362) and validation (n 5 225) patient cohort sets. 48 Both studies identified b-catenin as a protective prognostic indicator. Of the remaining 6 markers reported by Meyer et al, none were evaluated by Gould Rothberg et al; and, of the remaining 4 reported by Gould Rothberg et al, p21 and p16 were evaluated by Meyer et al, although that study did not examine the prognostic impact of nuclear staining only (p21) or nonnuclear/nuclear ratios (p16). In addition, in a cohort of 395 primary melanomas, Kashani-Sabet et al confirmed a protein-based prognostic signature that contained nuclear receptor coactivator 3 (NCOA3), secreted phosphoprotein 1 (SPP1) (osteopontin), and regulator of G-protein signaling 1 (RGS1), which they previously identified as prognostic, in a complementary DNA microarray-based study. 49 A multimarker index score of expression was established as an independent predictor of disease-specific survival (DSS) and SLN status and was validated in an independent patient cohort. It is noteworthy that, across multiple studies, it has been demonstrated that osteopontin is a prognostic factor, which we further detail below. In contrast to protein, mrna-based biomarkers can be robustly and quantifiably measured genome-wide using several methodologies and should be easily translatable into a highly quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) based clinical assay. However, such 4112 Cancer December 1, 2015
6 Determinants of Prognosis in Melanoma/Weiss et al TABLE 2. Prognostic Molecular Markers and Signatures Selected Genes Study Population and Method Clinicopathologic or Survival Associations Reference MCM3, MCM4, MCM6, KPNA2 KRT9, DCD, PIP, SCGB1D2, SCGB2A2, COL6A6, KBTBD10, ECRG2, HES6 Fresh-frozen primary melanomas (n 5 83); microarray IHC Fresh primary melanomas (n 5 41); microarray, RT-qPCR CD24, EVL Nonmetastasizing (stage I/II; n 5 116) and metastasized (stage III/IV; n 5 72) primary melanomas; SAGE BAP1, MGP, SPP1, CXCL14, CLCA2, S100A8, S100A9, BTG1, SAP130, ARG1, KRT6B, KRT14, GJA1, EIF1B, RBM23, LTA4H, CRABP2, DSC1, ROBO1, AQP3, SPRR1B, CST6, TRYP1, ID2, TACSD2, PPL Primary cutaneous melanomas (n 5 268) with semirandom stratification into 2 cohorts; RT-qPCR Genes (n 5 254) differentially expressed based on <4-y or > 4-y DMFS (n 5 58); IHC validation for 8 of 23 genes analyzed, 4 of which were associated with OS in a validation cohort (n 5 176) Genes (n 5 92) differentially expressed in primary melanomas between short-term (OS, < 4y;n520) and long-term (OS, > 5 y; n 5 21) survivors RT-qPCR analysis of 92 previously identified genes from Brunner ; 11 genes associated with OS in univariate Cox analyses were further measured in 53 additional primary tumors; 9 genes retained a significant association with OS Top 50 differentially expressed genes used for class prediction in 28 independent primary tumors; CD24 and EVL, alone or combined with Breslow thickness; provided the strongest predictor of outcome 20 Genes selected from mining of public data sets for genes consistently altered in primary vs metastatic melanoma; 5 additional genes prognostic in uveal melanoma (BAP1; 3 0 and 5 0 ends) and 1 gene originally selected as 1 of 4 reference genes comprise RT-qPCR based, 28-gene prognostic signature; radial basis machine modeling stratified patients into low-risk or high-risk groups, which clearly separated in Kaplan-Meier DFS curves; multivariate Cox analyses with key prognostic parameters indicated that this signature may be independently prognostic Same as above Subset of above Follow-up study examined 28-gene signature in 217 patients with primary melanoma who had undergone SLNB; in this patient cohort, the expression signature performed as well or better as an independent predictor of DFS, DMFS, and OS HOXA1 targets genes NA HOXA1 proinvasion transcriptional signature identified; the signature classified patient samples from Winnepennninckx CD2 Stage II (n 5 47) and III (n 5 48) FFPE primary melanomas; Nanostring mirna mir-382, mir-516b FFPE primary melanomas (n 5 92, n 5 119); mirna microarray 134 mirnas FFPE primary melanomas (n 5 82, n 5 97); mirna microarray A 53-gene panel of immunoregulatory genes in patients with stage II and III melanoma predicted nonprogression, RFS, and DSS Reported mirnas associated with tumor thickness and recurrence status, but focused on functional contributions to metastatic spread; 2 metastasissuppressor mirnas (mir-382 and mir-516b) were not clearly associated with survival parameters in multivariate analyses (data not reported) Reported mirna associated with nodular vs superficial spreading melanoma subtypes in primary melanoma tissues; prognostic implications within each subtype were not reported Winnepennninckx Brunner Brunner Gschaider Gerami Gerami Wardwell-Ozgo Sivendran Hanniford ,65 Poliseno Cancer December 1,
7 Review Article TABLE 2. Continued Selected Genes Study Population and Method Clinicopathologic or Survival Associations Reference mir-200 family, mir-203 Fresh-frozen primary melanomas (n 5 23); RT-qPCR mir-30d FFPE primary melanomas (n 5 92); mirna microarray mir-1908, mir-199a-3p, mir-199a-5p Primary melanomas (n 5 71); RT-qPCR mir-15b Primary melanomas (n 5 128); RT-qPCR Eleven mirnas (of 159 measured) associated with tumor thickness; in validation patient set, study observed progressive loss of mir-200a, mir-200c, and mir-203 expression from nevi, to primary, to metastasis and at the invasive front of primary tumors Prometastatic mir-30d expression associated with stage, thickness, histologic subtype, and RFS and OS in primary melanoma samples mir-1908, mir-199a-3p, and mir-199a-5p were up-regulated in a melanoma metastasis in vivo selection model; study observed univariate associations with metastasis-free survival in patient samples Expression of proproliferative mir-15b associated with poor RFS and OS in multivariate analyses; mir-34a and mir-210 did not associate with survival parameters van Kempen Gaziel-Sovran Pencheva Satzger Abbreviations: AQP3, aquaporin 3 (Gill blood group); ARG1, arginase 1; BAP1, breast cancer 1 (BRCA1)-associated protein-1 (ubiquitin carboxy-terminal hydrolase); BTG1, B-cell translocation gene, antiproliferative); CD2, cluster of differentiation 2 (cell adhesion molecule); CD24, cluster of differentiation 24 (heat stable antigen CD24); CLCA2, chloride channel accessory 2; COL6A6, collagen, type VI, a6; CRABP2, cellular retinoic acid binding protein 2; CST6, cystatin E/M; CXCL14, chemokine (C-X-C motif) ligand 14; DCD, dermcidin; DFS, disease-free survival; DMFS, distant metastasis-free survival; DSC1, desmocollin 1; DSS, disease-specific survival; ECRG2, esophageal cancer-related gene 2; EIF1B, eukaryotic translation initiation factor 1B; EVL, Enah/Vasp-like; FFPE, formalin-fixed, paraffin-embedded; GJA1, gap junction protein a1, 43 kda; HES6, hes family basic helix-loop-helix transcription factor 6; HOXA1, homeobox A1; ID2, inhibitor of DNA binding 2, dominant negative helix-loop-helix protein; IHC, immunohistochemistry; KBTBD10, kelch repeat and BTB domain containing protein 10; KPNA2, karyopherin a2 (RAG cohort 1, importin a1); KRT14, keratin 14, type I; KRT6B, keratin 6B, type II; KRT9, keratin 9, type I; LTA4H, leukotriene A4 hydrolase; MCM3, minichromosome maintenance complex component 3; MCM4, minichromosome maintenance complex component 4; MCM6, minichromosome maintenance complex component 6; MGP, matrix Gla protein; mir, microrna; mrna, messenger RNA; NA, not available; OS, overall survival; PIP, prolactin-induced protein; PPL, periplakin; RBM23, RNA binding motif protein 23; RFS, recurrence-free survival; ROBO1, roundabout guidance receptor 1; RT-qPCR, quantitative reverse transcriptase-polymerase chain reaction; S100A8, S100 calcium-binding protein A8; S100A9, calcium-binding protein A9; SAGE, serial analysis of gene expression; SAP130, Sin-3A-associated protein, 130 kda; SCGB2A2, seroglobin, family 2A, member 2; SCGB1D2, secretoglobin, family 1D, member 2; SLNB, sentinel lymph node biopsy; SPP1, secreted phosphoprotein 1; SPRR1B, small proline-rich protein 1B; TACSD2, tumor-associated calcium transducer 2; TRYP1, tryparedoxin peroxidase. studies are limited by poor-quality mrna obtained in archival FFPE tissues. 13,50 Moreover, contamination from infiltrating cells and the surrounding microenvironment likely result in significant expression bias and complicate cross-study comparisons. There are numerous reports documenting mrna expression profiling of melanoma cell lines and metastatic melanoma tissues or comparisons across melanoma progression (nevi, primary, metastasis) However, only a few studies have examined gene expression profiling or have developed mrna-based prognostic signatures in primary melanoma tissues from patients who had different outcomes (Table 2). Winnepenninckx et al reported mrna expression profiles for 83 fresh-frozen, primary cutaneous melanomas in which they defined a set of 254 genes that had differential expression based on 4-year distant metastasis-free survival (DMFS), and they identified high expression of minichromosome maintenance (MCM) genes as key predictors of reduced DMFS. 56 A follow-up study reanalyzed those data in the context of biologic pathways and revealed that high expression of DNA repair genes was associated with poor DMFS. 71 It is noteworthy that another recent study, in which a proinvasive homeobox A1 (HOXA1) transcriptional signature was defined, indicated that patients from the study by Winnepenninckx et al who had a high HOXA1 signature had poor DMFS, adding an intriguing underlying transcriptional mechanism to the original expression findings, although the authors did not note whether DNA repair pathway genes were highly represented in their signature. 62 A second primary cutaneous melanoma expression-profiling study identified 92 genes associated with OS 57 ; and a subsequent follow-up study, which further assessed those 92 genes, reported that a 9-gene signature (6 protective and 3 unfavorable genes) was associated with OS in a 91-patient cohort. 58 A recent report used serial analysis of gene expression to identify differentially expressed transcripts between 116 primary tumors that had not metastasized 4114 Cancer December 1, 2015
8 Determinants of Prognosis in Melanoma/Weiss et al (stage I/II) and 72 primary tumors that had already spread at the time of initial diagnosis (stage III/IV). 59 Subsequent multivariate class-prediction analyses of the top 50 differentially expressed genes identified CD24 (heat-stable antigen CD24) and Enah/Vasp-like (EVL) as strong predictors of metastatic risk in an independent set of 28 primary melanoma samples. Conway et al 72 performed complementary DNA-mediated annealing, selection, extension, and ligation expression profiling of 502 cancer genes on >350 FFPE cutaneous primary melanomas from 2 patient cohorts and observed that high osteopontin (SPP1) expression was associated with reduced RFS, which confirmed previous findings. 51,73,74 Osteopontin has been implicated in cell motility, proliferation, and activation of the nuclear factor-jb pathway, which may add mechanistic explanations for its prognostic capacity. 73 A subsequent reanalysis of those data by the same group associated the increased expression of DNA repair genes with poor RFS, 75 consistent with the described reanalysis of the data reported by Winnepenninckx et al. 71 Collectively, those studies reported from tens to hundreds of genes associated with metastatic risk and/or survival outcomes in primary cutaneous melanoma. No reported genes overlapped in more than 2 studies. Of the 50 genes reported by Gschaider et al, 59 7 genes overlapped with those reported by Winnepenninckx et al, 56 although it is noteworthy that the cellular source of those RNAs is likely to be keratinocytes, endothelial cells, or infiltrating immune cells, which would support the microenvironment and/or the host response as key prognostic markers for patient outcomes in primary cutaneous melanoma (Supporting Table 1; see online supporting information). Five genes in a combined list from Conway et al and Jewell et al overlapped with those reported by Winnepenninckx et al, and osteopontin overlapped between the studies by Conway/Jewell et al and Gschaider et al. None of the 92 genes that originally were associated with OS by Brunner et al 57 and further assessed in a follow-up study 58 overlapped with genes reported in the other studies, although we note that none of the other studies defined genes that were directly associated with OS. Two recent studies by Gerami and colleagues selected a set of 28 gene targets (melanoma metastasisassociated genes identified from data mining, previously defined prognostic uveal melanoma genes, and breast cancer 1-associated protein-1 [ubiquitin carboxy-terminal hydrolase] [BAP1]) for analysis as a prognostic molecular signature in melanoma. 60,61 In their first study, the gene set was measured in 268 primary melanoma patient samples, which were mostly randomly stratified to a training cohort (n 5 164) and a validation cohort (n 5 104). 61 In the second study, the analysis of gene set measurements was restricted to patients who had undergone an SLN biopsy (SLNB) procedure. Prognostic modeling was performed using radial basis machine modeling to separate patients into 2 risk classes, which were plotted on Kaplan- Meier survival curves and compared with AJCC stage, Breslow depth, ulceration, mitotic rate, and age or SLN status in univariate and multivariate analyses. Both studies indicated that the defined signature was an independent predictor of metastatic risk. Those studies are the basis of a clinical prognostic test (DecisionDx) offered by Castle Biosciences (Friendswood, Tex), which is discussed below. EXPRESSION OF MIRNA A newer class of RNA mirna has been of particular interest to cancer researchers over the last decade. Although fewer in number than mrnas and not translated to protein, mirnas are ideal potential biomarkers because they are quantifiable genome-wide and are highly stable in FFPE tissues, 76,77 although they are equally affected by sample purity as are mrna. mirna expression profiling has typically been performed using microarrays (genome-wide, but inconsistently quantitative) or RT-qPCR (fewer mirnas, but highly quantitative), although newer technologies, including RNA-sequencing and Nanostring, allow highly quantitative genome-wide analyses. Early studies of global mirna expression in primary melanoma did not focus on prognosis but, rather, on the identification of mirnas that play functional roles in melanoma tumorigenesis Our group reported 18 mirnas that were associated with post-recurrence survival, 83 and a subset of 6 of those mirnas (mir-150, mir-342-3p, mir-455-3p, mir-145, mir-155, and mir- 497) was defined as a post-recurrence survival signature. It is worth noting that mir-342-3p is located in an intron of its host gene EVL, which was recently associated with metastatic risk in primary melanoma. 59 Another recent study replicated the prognostic importance of mir-150 and mir-142 (from the 18 mirnas that were associated with postrecurrence survival) 83 in stage III lymph node metastases and patient sera. 84 We recently reported the identification of metastasissuppressive mirnas that we originally identified as differentially expressed in array-based global mirna profiling of primary cutaneous melanoma tissues (2 cohorts of 92 and 119 patient samples). 64 We observed that these mirnas were associated with thickness, recurrence status, and/or Cancer December 1,
9 Review Article RFS. From those data, we defined a 4-miRNA signature (mir-150, mir-15b, mir-16-5p, andmir-374b-3p) that, in combination with AJCC stage, was predictive of developing brain metastasis. 65 Our group also reported a series of 134 mirnas that were differentially expressed in nodular melanoma (n 5 56) versus superficial spreading melanoma (n 5 26) histologic subtypes, controlling for stage 66 ; however, the possibility that selected mirna signatures have independent prognostic importance for these subtypes has not yet been explored. van Kempen et al performed expression profiling of 159 mirnas using RT-qPCR in 23 fresh-frozen melanoma samples. 67 In their patient cohort, 11 mirnas were associated with tumor thickness. In a validation patient set, expression analysis of those 11 mirnas and further in situ hybridization revealed loss of mir-200 family (mir-200a and mir-2900c)and mir-203 expression during melanoma progression and at the invasive front in primary tumors. Of the mirnas that were consistently correlated with tumor thickness in our patient cohorts (n 5 27 mirnas), 10 were measured in the study by van Kempen et al; 4 of those 10 (mir-200b, mir-200c, mir-203, and mir-205) were correlated with thickness; and each maintained the same direction as in our data (Supporting Table 2; see online supporting information). Of the 11 mirnas reported by van Kempen and colleagues, there was evidence of a correlation with thickness for 9 in at least 1 of our data sets, and the directions of all correlations were maintained between studies. Several other studies identified mirnas that play functional roles in the proliferative or invasive/metastatic capacity of melanoma cells based on analyses of mirna expression and associations with patient outcomes. Our group previously reported that high expression in primary melanoma tissues of mir-30d, a prometastatic mirna that regulates glycosylation and immune suppression in melanoma, is associated with advanced stage, increased thickness, nodular histologic subtype, and poor RFS and OS. 68 Another recent study used in vivo selection in mice to generate highly metastatic melanoma cell line variants. 69 The mirnas mir-1908, mir-199a-3p, and mir-199a-5p, which are highly up-regulated in these metastatic variants and are critical drivers of melanoma progression, were inversely associated with metastasis-free survival in a cohort of 71 primary melanoma samples, although multivariate analyses were not performed, and patient characteristics were not reported. Several reports have defined loss of mir-211 expression as a key feature of melanoma cells, and its overexpression is suppressive of melanoma cell proliferation and invasion in vitro. 80,82,85 Surprisingly, however, no studies have yet reported any association of mir-211 expression in primary tumors with patient outcomes. In this regard, the results from 1 of our recently published data sets, which included a set of congenital nevi, are supportive of decreased abundance of mir-211 in primary melanoma compared with nevi. 64 However, mir-211 expression in those tumors was not clearly associated with prognostic parameters or patient outcomes in the data set (data not shown). Finally, Satzger et al reported that high expression of the proproliferative mirna mir-15b in a set of 128 primary melanoma tissues was significantly associated with poor outcomes (RFS and OS) in multivariate analyses. 70 Overall, these studies have demonstrated the potential utility of mirna expression-based prognostic assays; however, there is limited overlap of the key mirnas reported as prognostic in these studies, and sample sizes remain modest. Based on tissue and serum studies (described below), mir-150 and mir-15b are associated the most consistently with prognosis in patients with primary and metastatic melanoma. IMMUNE MARKERS OF THE HOST Tumor-Infiltrating Lymphocytes Immunologic markers are being studied as prognostic tools that may enhance outcome predictions and could be incorporated into traditional TNM melanoma staging. For example, the Immunoscore has been designed to prognosticate early stage colon cancer patients based on CD3-positive, CD8-positive, and CD45-positive lymphocyte densities within tumors. High Immunoscores in colon cancer are associated with improved RFS and OS. 86 Tumor-infiltrating lymphocytes (TILs) have been investigated across multiple malignancies for decades as a surrogate for antitumor immune response; however, current cancer staging systems do not incorporate TIL status. There is debate concerning whether TIL status is clearly associated with melanoma prognosis (Table 3). Clark et al reviewed 98 primary melanomas for 8 pathologic variables, including tumor-infiltrating lymphocytes (TILs), which were assigned 1 of 3 grades as measured in the vertical growth phase: brisk (lymphocytes infiltrate the entire vertical growth phase or tumor base), nonbrisk (lymphocytes are focally present in the vertical growth phase), or absent (lymphocytes may be present in fibrotic areas or near vessels but do not infiltrate the vertical growth phase). TIL grade was significantly correlated with 8-year OS. 87 Since then, data in the literature both 4116 Cancer December 1, 2015
10 Determinants of Prognosis in Melanoma/Weiss et al support 90,94-96 and refute 88,91-93 the prognostic relevance of absent, nonbrisk, and brisk TILs in primary melanomas. Azimi and colleagues scored 1865 primary melanomas using a different TIL grading system with a score that ranged from 0 to 3 and demonstrated that TIL grade was inversely associated with SLN status. TIL grade 0 was associated with a 27.8% rate of SLN positivity compared with a rate of only 5.6% for TIL grade Higher TIL grade also was significantly associated with longer RFS and MSS (survival rate, 100% vs 75% for TIL grades 3 vs 0, respectively; median follow-up, 43 months). Multivariate analysis demonstrated that the strongest predictors of RFS were thickness, ulceration, and TIL grade. 94 Similarly, in 887 patients who underwent SLN mapping, Taylor et al demonstrated that the absence of TILs was predictive of SLN positivity in both univariate and multivariate analysis; however, in contrast to the results of Azimi et al, there was no difference in DFS or OS. 91 There are several reasons for the discrepancies in TIL grade among studies. Studies differ by sample size, patient population, characteristics of the primary tumors, and even method of grading TILs. For example, Clemente et al examined 285 primary melanomas, of which 82% were thicker than 2 mm, and observed an association of TIL grade with survival. 89 In contrast, Barnhill et al studied 548 primary melanomas with a higher proportion of thinner tumors (43% measured < 0.76 mm in thickness) in which there was no significant difference in OS based on TIL grade. 88,89 It is believed that TILs are more frequent in thin melanomas 91 ; and; in a study of 293 highrisk primary melanomas (thickness > 4 mm), TIL grade did not correlate significantly with survival outcomes, although there was a trend toward improved RFS survival for the presence of TILs. 97 Furthermore, studies vary in the TIL groups they compare for their survival analyses. Some only compare absent versus present TIL grade 88,91 without separating out the brisk and nonbrisk groups, whereas others group nonbrisk and absent TIL grades 90 or do not address absent TILs at all, 93 which makes crossstudy comparisons challenging. The identification of balance between immunostimulatory and immunosuppressive T-cell populations within the lymphocytic infiltrates is an overlooked consideration. For example, in a study of CD3, CD8, CD20, and forkhead box P3 (Foxp3) IHC expression on lymph nodes that were positive for melanoma, the ratios of peritumoral to intratumoral TILs for both CD3 and CD8 expression were lower in patients who developed recurrent melanoma. 96 In metastatic melanoma, Erdag et al characterized immunotypes A, B, and C, which roughly compare with absent, nonbrisk, and brisk TIL grades, and demonstrated differences in the median OS rate (15, 23, and 130 months, respectively) as well as differences in the cellular composition of the immune infiltrate present in each immunotype. 99 Higher densities of CD8-positive T cells and CD45- positive leukocytes, T cells, and B cells were associated with improved survival. There was no correlation of Foxp3, a regulatory T-cell marker, with survival. The proportion of B cells was highest in immunotype C, and the proportion of macrophages was lowest in immunotype C. 99 Immunoregulatory Gene Expression Levels A newer area of investigation beyond pathologic TIL classification is aimed at identifying differentially expressed genes with immunoregulatory functions, with the hope of characterizing prognostic immune biomarkers. This is now possible with the advent of efficient, high-throughput technology, such as Nanostring, that can quantify gene expression levels for up to 800 genes of interest from small amounts of RNA isolated from FFPE tissue. Recently, a 53-gene immune panel proposed from an initial set of 446 genes was tested for prognostic value using Nanostring technology in RNA isolated in melanomas from 47 patients with stage II and III disease. 63 The gene signature was identified as predictive of nonprogression, RFS, and DSS. The candidate genes are important for T-cell and natural killer cell function and leukocyte migration, and they are involved in immune surveillance pathways. For example, C-C chemokine receptor type 5 (CCR5), CD8, CD3, and IKAROS family zinc finger 1 (IZKF1), were more highly expressed in patients who did not progress. Specifically, the most differentially expressed gene was CD2, a costimulatory molecule expressed on T cells and natural killer cells. Increased CD2-positive cells are correlated with melanoma nonprogression, as confirmed by IHC. 63 The Cancer Genome Atlas recently reported a distinct immunologically characterized subgroup of cutaneous melanomas that predict improved survival outcomes. Regional melanoma lymph nodes were examined for a lymphocyte score (LScore), which was calculated based on the density and location of TILs, with higher LScores correlating with prolonged survival and stratification into the immune subclass. In addition, elevated expression of the LCK (proto-oncogene, Src family tyrosine kinase) and SYK (spleen tyrosine kinase) nonreceptor tyrosine kinases involved in lymphocyte signaling were identified in the immune subgroup, and a correlation of increased LCK gene expression and improved survival was observed. 100 Although the differing study designs and patient populations challenge our understanding of the prognostic Cancer December 1,
11 Review Article TABLE 3. Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas and Association With Survival Outcomes No. of Patients Survival Associations Comments Reference 264 Predicts 8-y OS (TILs: brisk, 88%; Clark nonbrisk, 75%; absent, 59%) 548 No survival differences Compared absent vs present TILs only Barnhill Predicts 5-y OS (TILs: brisk, 77%; Clemente nonbrisk, 53%; absent, 37%) 259 Predicts 5-y OS (TILs: brisk, 100%; Groups with nonbrisk and absent TILs Tuthill nonbrisk and absent, 71%) were included in the analysis 887 No survival differences Groups with nonbrisk and brisk TILs Taylor were included in the analysis 1251 No survival differences Mandala Predicts 5-y OS (TILs: brisk, 95%; Did not address absent TILs Burton nonbrisk, 84%) 1865 Predicts 5-y OS Used their own TIL grading system Azimi assigning a score from 0 to Predicts 5-y OS (TILs: brisk, 97%; nonbrisk, 94%; absent, 93%) Thomas Abbreviations: OS, overall survival; TILs, tumor-infiltrating lymphocytes. value of TILs, the role of the host antitumor immune response in melanoma cannot be ignored. Future studies characterizing immune phenotypes and perhaps an Immunoscore or quantitative molecular markers of host responses are needed to better assess the correlation of TILs with clinical outcomes. Gene expression analyses of immunoregulatory genes like that by Sivendran et al may identify key immunologic markers that can be linked with current known AJCC prognostic factors or molecular markers for more accurate outcome predictions. SERUM MARKERS Although the serum marker lactate dehydrogenase is incorporated into the AJCC staging system for the substaging of metastatic (stage IV) melanoma, no serumbased biomarkers have been identified that would meet criteria for incorporation into the staging system for earlier stage melanoma (predictive of relapse) or to provide better prognostic or therapeutic guidelines in advanced melanoma. Melanoma-inhibitory activity protein (MIA) is produced and secreted by melanoma cells. In a cohort of 84 patients with stage I and II cutaneous melanoma who were followed prospectively, high versus low serum MIA concentrations were associated with increased recurrence (66% vs 5%) and reduced DFS at 4 years (30.3% vs 94.5%). 101 Serum levels of S100B, a protein involved in microtubule assembly and inhibition of the tumor suppressor p53, increase progressively in each stage of melanoma and associate negatively with survival. 102,103 C-reactive protein (CRP) is an acute-phase reactant that is elevated in numerous clinical scenarios, including states of infection, inflammation, and malignancy. The measurement of elevated serum CRP levels may be superior to serum lactate dehydrogenase measurements in identifying patients who progress to metastatic melanoma. 104 In multivariate analyses, serum CRP levels measured at the time of primary melanoma resection and then sequentially thereafter revealed an association between elevated CRP levels and worse OS, MSS, and DFS in patients with stage I and II melanoma, suggesting that serum CRP may be a valuable prognostic biomarker in melanoma. 105 Two studies by our group examined the utility of serum-based mirna abundance for prediction and surveillance of recurrence in patients with melanoma. 106,107 Friedman et al defined a 5-miRNA signature from sera isolated in blood obtained at diagnosis from 80 patients with primary melanoma that classified patients into high-risk and low-risk groups, which separated well in Kaplan-Meier RFS curves. In a follow-up study, we also developed a refined, 4-miRNA, serabased signature (mir-150, mir-15b, mir-30d, and mir-425) adjusted for AJCC stage to define low-risk and high-risk patients, which stratified patients by RFS and OS into 2 cohorts (n and n 5 82, respectively). 106 Finally, there is interest in measuring circulating tumor DNA (ctdna) in patients with advanced melanoma as an early indicator of response to treatment. 108,109 Although ctdna measurements are not currently used in clinical practice, prospective studies will address whether ctdna can be used as a blood-based biomarker to detect melanoma recurrence Cancer December 1, 2015
> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationUpdate on Lymph Node Management in Melanoma
Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline
More informationI have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine
Molecular Characterization of Stage 1-3 Melanoma: Are we close to accurate prognostication and prediction? I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationUpdate on Genetic Testing for Melanoma
Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD
More informationGene Expression Profiling in Malignancies: New Insights into Cancer Care
Gene Expression Profiling in Malignancies: New Insights into Cancer Care Surgical Grand Rounds February 8, 2017 Martin Fleming, M.D. Chief, Division of Surgical Oncology West Cancer Center University of
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationPatricia Chevez-Barrrios AAOOP-USCAP /12/2016
Biomarkers in Ocular Melanoma Patricia Chévez-Barrios, MD Pathology and Genomic Medicine, Houston Methodist Hospital Professor of Pathology and Laboratory Medicine and Ophthalmology, Weill Cornell Medical
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationGene Expression Profiling for Melanoma
Medical Policy Manual Genetic Testing, Policy No. 29 Gene Expression Profiling for Melanoma Next Review: April 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are
More informationWhich melanoma patients benefit from genetic testing?
Which melanoma patients benefit from genetic testing? Michael A. Marchetti, MD Assistant Attending, Dermatology Service Memorial Sloan Kettering Cancer Center American Academy of Dermatology Annual Meeting
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationSupplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the
Supplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the genome-wide methylation microarray data. Mean ± s.d.; Student
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationSUPPLEMENTARY APPENDIX
SUPPLEMENTARY APPENDIX 1) Supplemental Figure 1. Histopathologic Characteristics of the Tumors in the Discovery Cohort 2) Supplemental Figure 2. Incorporation of Normal Epidermal Melanocytic Signature
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationOncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this study the authors analysed 18 deep penetrating nevi for oncogenic genomic changes (single nucleotide variations, insertions/deletions,
More informationTrue or False? Nearly twice as many SLNB negative compared to SLNB positive patients will ultimately die of metastatic melanoma.
qrt-pcr Based Methods for Prognosis of Melanoma Pedr am Gerami MD Pr ofessor of Dermatology, Pathology and Pediatrics Nor thwestern University Dir ector Melanoma Program, Northwestern Skin Cancer Institute
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationChallenges in Melanoma Diagnosis and Management
Challenges in Melanoma Diagnosis and Management Winter Clinical Dermatology Conference - Hawaii Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center DISCLOSURE OF
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationElevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma
1142 Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma FARUK TAS and KAYHAN ERTURK Department of Medical Oncology,
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationGene Expression Profiling for Cutaneous Melanoma
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information2/6/2018. Original Paradigm. Clonal Chromosomal A berrations. Only 20% of Spitz Nevi 95% 6p, 7q, 17q, 20q, 4q,8q, 1q, 11q. Isolated Gain in 11p
Molecular Diagnostics for Melanocytic Neoplasms: Moving towards a Revolution in the Management of Melanocytic Neoplasms Pedr am Gerami MD Associate Professor of Dermatology, Pathology and Pediatrics at
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationGene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma.
Last Review Status/Date: September 2014 Description Page: 1 of 5 Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma. Background Uveal melanoma Uveal melanoma,
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationCase Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
Case Reports in Oncological Medicine Volume 2016, Article ID 2672671, 4 pages http://dx.doi.org/10.1155/2016/2672671 Case Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationTriple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationDISCOVERY AND VALIDATION OF PROGNOSTIC MARKERS FOR CUTANEOUS MELANOMA
From the DEPARTMENT OF ONCOLOGY-PATHOLOGY Karolinska Institutet, Stockholm, Sweden DISCOVERY AND VALIDATION OF PROGNOSTIC MARKERS FOR CUTANEOUS MELANOMA Johan Falkenius Stockholm 2018 All previously published
More informationPrognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma
ORIGINAL ARTICLE Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma Rita G. Ladstein 1, Ingeborg M. Bachmann 1,2, Oddbjørn Straume 1 and Lars A. Akslen 1,3 Mitotic
More information21/07/2017. The «gray zone» of diagnosis is visible. Nevus Atypical nevus Melanoma. Melanoma ex-blue nevus
Update on the Clinico- Pathological and Molecular Diagnosis of Melanocytic Lesions None to declare Conflicts of interest Belfast pathology Arnaud de la Fouchardière MD, PhD Lyon, France What is new? Today
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationHuman Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop
Human Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop Jan 7 th and 8 th, 2014 Brigitte Gomperts, MD University of California, Los Angeles Lung Structure and Function Airway Epithelial
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More information